Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза II Россия

ONC1-0013B

Открытое рандомизированное исследование фазы II препарата ONC1-0013B для оценки безопасности, переносимости, фармакокинетики и эффективности, c целью определения терапевтической дозы у пациентов с метастатическим кастрационно-резистентным раком предстательной железы, ранее не получавших химиотерапию

Разрешение№ 245 от 15.05.2019
Номер протоколаCL01069052
ФазаФаза II
Участников по плану150
Сроки15.05.2019 — 26.03.2023
РазработчикАО «Р-Фарм»
Страна разработчикаРоссия
Начало: 15 мая 2019Окончание: 26 марта 2023
Плановый срок исследования истёк
Статус рассчитан по плановой дате окончания. В реестре указано: «Проводится».

Постоянная ссылка: https://clinomir.ru/trials/permit/ru/245/2019-05-15/

Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет, только мужчины. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 150 чел. в стране «Россия».
  • Центров в реестре: 2 в 2 городах. Список — ниже на странице.
  • Плановая дата окончания (03.2023) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолТолько мужчины
Здоровые добровольцынет

Главное из критериев

  • Состояние пациента (ECOG)0–1
  • Предшествующее лечениеранее не лечились (первая линия)
  • Биомаркеры в критерияхEGFR
  • Опухольнужен измеримый очаг (RECIST)
  • Стадияметастатическая (IV)
  • Ожидаемая продолжительность жизнине меньше 24 нед.
  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 21 · невключение: 40

Критерии включения

  • Voluntarily signed and dated Informed Consent Form (ICF) of the patient agreed to take part in this Study
  • Histologically confirmed diagnosis of prostate adenocarcinoma showing no neuroendocrine, signet-ring cell, small cell, or ductal differentiation
  • Ongoing androgen deprivation therapy for prostate cancer aimed at testosterone suppression with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist at a stable dose and schedule for at least 4 weeks immediately prior to Day 1, or a history of bilateral orchiectomy (i.e., medical or surgical castration). Patients who have not undergone bilateral orchiectomy must agree to continue effective continuous LHRH analogue therapy throughout the study
  • Serum testosterone level ≤ 50 ng/dL (1.73 nmol/L)
  • Prostate-specific antigen (PSA) level > 2 ng/mL
  • Evidence of progressive disease at the time of randomization, defined by one or more of the following criteria:
  • PSA progression, defined as at least two consecutive increases in PSA levels occurring ≥ 2 weeks apart, with at least one increase documented during screening; the PSA level at screening must be ≥ 2 ng/mL
  • Soft tissue disease progression based on computed tomography (CT) or magnetic resonance imaging (MRI) assessment per RECIST v1.1
  • Bone disease progression based on bone scintigraphy findings
  • Disease progression occurring during androgen deprivation therapy or during or after docetaxel chemotherapy administered as first-line treatment for metastatic hormone-sensitive prostate cancer
  • Asymptomatic or mildly symptomatic prostate cancer, defined as a score < 4 on Question 3 of the Brief Pain Inventory-Short Form (BPI-SF)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy ≥ 24 weeks
  • Major organ function must meet the following criteria:
  • Absolute neutrophil count (ANC) ≥ 1,500/mm\^3 (1.5 × 10\^9 cells/L)
  • Platelet count ≥ 100,000/mm\^3 (100 × 10\^9 cells/L)
  • Hemoglobin ≥ 90 g/L
  • Total bilirubin ≤ 1.5 × ULN
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN, or ≤ 3 × ULN in the presence of liver metastases
  • Serum creatinine < 1.5 × ULN or estimated glomerular filtration rate (eGFR) > 45 mL/min, calculated using CKD-EPI equations
  • Fertile male patients must agree to abstain from heterosexual intercourse or to use highly effective methods of contraception, starting from the date of signing the informed consent form, throughout the entire study treatment period, and for at least 28 days after investigational product/comparator discontinuation

Критерии невключения

  • Presence of central nervous system (CNS) metastases that are progressive or associated with clinical symptoms (e.g., cerebral edema, spinal cord compression), or requiring treatment with glucocorticoids and/or anticonvulsants. Patients with brain metastases may be enrolled in case adequate treatment (surgery and/or radiotherapy) has been completed and radiographic stability has been documented for at least 4 weeks prior to the planned date of randomization. Newly diagnosed CNS metastases identified during screening that are asymptomatic and do not require treatment are not considered an exclusion criterion
  • Prior antitumor therapy:
  • Radiotherapy (except palliative irradiation of bone lesions for pain control) within 4 weeks prior to the planned date of randomization
  • Prior treatment with first-generation antiandrogens (flutamide, bicalutamide, nilutamide) within 4 weeks prior to the planned date of randomization
  • Prior treatment with second-generation antiandrogens (enzalutamide, apalutamide, darolutamide)
  • Use of bisphosphonates or denosumab is permitted only if treatment was initiated prior to the planned date of randomization
  • Clinically significant cardiovascular disease, including:
  • Myocardial infarction within 6 months prior to the planned date of randomization
  • Unstable angina within 3 months prior to the planned date of randomization
  • Chronic heart failure NYHA class III or IV
  • Clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation)
  • QTc interval > 460 ms on ECG (calculated using Fridericia formula), or long QT syndrome identified at screening
  • Left ventricular ejection fraction ≤ 50% by echocardiography
  • Hypotension (systolic blood pressure < 80 mmHg) or bradycardia (heart rate < 50 bpm), except when drug-induced (e.g., beta-blockers), at the time of the planned randomization
  • Uncontrolled arterial hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 105 mmHg) at the time of the planned randomization
  • Clinically significant CNS disorders, including:
  • History of seizures or conditions that may predispose to seizure development
  • Presence of stroke or transient ischemic attack within 12 months prior to the planned date of randomization
  • Primary brain tumors, cerebral arteriovenous malformations, meningiomas, schwannomas, or other benign CNS disorders that may require surgical or radiation treatment (patients with such conditions may be enrolled if no surgical or radiotherapy intervention is required)
  • Traumatic brain injury or loss of consciousness within 12 months prior to the planned date of randomization
  • Presence of untreated spinal cord compression or any other severe or systemic disease increasing the risk of treatment-related complications
  • Presence of clinically significant pituitary or adrenal dysfunction that cannot be adequately controlled with stable-dose hormonal or other standard therapy for at least 28 days prior to the planned date of randomization
  • History of another malignancy that is progressive or required anticancer treatment (including hormonal therapy) within 5 years prior to the planned date of randomization, except curatively treated basal cell or squamous cell carcinoma of the skin
  • History of other significant comorbid conditions that, in the investigator's opinion, may worsen during the study, including uncontrolled diabetes mellitus
  • Prior or concomitant therapy:
  • Use of medications that may induce seizures within 4 weeks prior to the planned date of randomization
  • Use of inhibitors or inducers of CYP3A4 or CYP2D6 within 4 weeks prior to the planned date of randomization
  • Use of medications classified as QT prolongation risk class I within 4 weeks prior to the planned date of randomization; QT risk class II medications are permitted if administered at a stable dose for at least 5 half-lives prior to the planned date of randomization
  • Prior or concomitant treatment with 5-alpha reductase inhibitors or anabolic steroids within 6 months prior to the planned date of randomization
  • Prior systemic glucocorticosteroid therapy at doses equivalent to ≥ 10 mg prednisone within 3 months prior to the planned date of randomization, except corticosteroids administered following brain irradiation, if treatment has been completed prior to enrollment in the study
  • History of allergic reactions, including reactions to medicinal products or food, that are clinically significant, in the opinion of the investigator
  • Presence of conditions limiting the patient's ability to comply with protocol requirements, including dementia, neurological or psychiatric disorders, substance or alcohol abuse, or religious or personal beliefs potentially limiting standard treatment during the study. Patients receiving narcotic analgesics for pain control may be enrolled.
  • Concurrent participation in another interventional clinical trial within 30 days prior to signing the informed consent form (if at least one dose of investigational product/comparator was received), or prior participation in this study (if at least one capsule of RS-113 or one tablet of abiraterone was administered by the patient)
  • Acute infectious diseases or exacerbation of chronic infections within 14 days prior to the planned date of randomization
  • Presence of current hepatitis B or C infection, evidence of HIV infection or active syphilis
  • Use of live vaccines within 30 days prior to the planned date of randomization. For patients receiving approved SARS-CoV-2 vaccines, the instructions for use and/or local requirements must be followed. Use of the Sputnik V vaccine is permitted provided that at least 7 days have elapsed between administration of the second vaccine dose and the first dose of the investigational product
  • Inability to swallow the investigational or comparator product
  • Inability to administer intravenous contrast
  • Presence of hypersensitivity (grade ≥ 3) to any component of RS-113, abiraterone, prednisone, or LHRH agonists (goserelin, leuprorelin, triptorelin, buserelin)
  • Presence of any other significant concomitant disease or condition that, in the investigator's reasonable judgment, may adversely affect the patient's participation, safety, or interpretation of study results

Источник: ClinicalTrials.gov, NCT07553988 · запись обновлена в реестре 28 апреля 2026.

Дизайн и результаты

ДизайнРандомизированное, открытое (без ослепления), параллельные группы; цель — лечение
Участников по плану (все страны)120
Результатыв реестре не опубликованы
Что измеряют — первичные конечные точки (1), вторичных — 19
  • Median Progression-free survival (PFS) at 1 year in RS-113 treatment arms — Up to day 337 (visit 16)

Цель исследования

The primary objective of the study is to determine the therapeutic dose of RS-113 in patients with metastatic castration-resistant prostate cancer based on efficacy, safety, and pharmacokinetic parameters. The secondary objectives are to assess a pilot efficacy and safety of different doses of RS-113 versus abiraterone, as well as to investigate pharmacokinetics profile and to perform a pilot evaluation of pharmacokinetics parameters of RS-113 in patients with metastatic castration-resistant prostate cancer

Области и заболевания

Где проходит

2 центра в 2 городах

Откуда эта информация

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.